Why Some Coaches Are Quietly Moving Their Clients From Anabolics Toward Peptides (A Cultural Read, Not a Recommendation)
A pseudonymous reader on the cultural drift inside fitness coaching, what the human evidence actually says about the peptides being pitched as substitutes, and why “softer” is doing more work than the data justifies.
by JoyBoy
13 min read
Last reviewed May 2026
Cultural observation
Most peptides discussed are not FDA approved
Why I looked into this
If you spent any time in fitness coaching content between roughly 2018 and 2025, you saw the same drift I did. Coaches who used to talk openly about anabolic-androgenic steroids for their long-term clients started talking, in the same breath, about peptides. The framing was almost always the same: as clients aged, as the risk conversations got harder, the suggestion was that peptides were the “softer” path forward.
I am not in that coaching world. I am a reader. But the volume of search traffic around this question is enormous, and the honest answer to it is not the one most of the content gives. So I went and read what is actually in the human literature on the peptides being pitched as substitutes. I want to write the piece I wish someone had written when I first noticed the trend.
This article is a cultural observation. It is not a how-to. It is not a comparison of which class is safer. It is a description of a shift, plus an honest accounting of what the data does and does not say about the peptide side of the trade.
What the shift looks like (and what it does not)
The cultural pattern I am describing has three parts. First, an aging coaching client base. The lifters who came up in the late 1990s and 2000s are now in their forties and fifties, and the risk calculus around anabolic-androgenic steroids reads differently at that age than it did at twenty-five. Second, a parallel rise in peptide content on YouTube, podcasts, and gym-bro forums starting around 2018, accelerating sharply through 2022. Third, a rhetorical bridge: coaches publicly talking about “transitioning” their clients toward peptides, with the implicit promise that the new direction is gentler.
What the shift is not, at least not in any rigorous sense, is a clinical transition. The peptides being pitched as substitutes (BPC-157, TB-500, the GH-axis family) are not in the same pharmacological category as anabolic-androgenic steroids and do not produce the same effects. They are also, with the partial exception of one approved GHRH analog used in a very specific patient population, not approved for use in healthy adults. The substitution framing flattens a lot of complexity that matters.
What the human research shows
What is the human evidence for the peptides most often pitched as substitutes?
The peptides showing up in this corner of the coaching content are predominantly recovery and GH-axis molecules. Here is what the human literature actually has on each:
- BPC-157: zero published randomized controlled trials in humans. The reputation rests on animal work that has not been replicated in human trials.
- TB-500 (Thymosin Beta-4): limited observational human data, no large RCTs in healthy adults. The strongest human signals are in narrow ophthalmologic and dermatologic settings, not in performance contexts.
- Sermorelin, Ipamorelin, CJC-1295, Hexarelin: mixed human data. Some short-term studies show GH-axis activation. None establish long-term safety or body-composition outcomes in healthy adults of the kind being implied in coaching content.
- Tesamorelin: the strongest human evidence in this group, with multiple RCTs. Approved by the FDA for HIV-associated lipodystrophy. The evidence base does not extend to healthy adults seeking body recomposition.
What does the strongest peptide evidence base actually cover?
The peptides with the most robust human RCT data are the GLP-1 family: Semaglutide, Tirzepatide, and (in Phase 2) Retatrutide. These molecules have multiple Phase 3 programs, cardiovascular outcomes data, and clear FDA-approved indications.
None of them are appetite-and-metabolism molecules being pitched as anabolic substitutes. They are not muscle-building agents. They are not framed in coaching content as a swap for anabolic-androgenic steroids, because they do not do what anabolic-androgenic steroids do. The peptides with the strongest human evidence base sit in a completely different conversation than the one this article is describing.
What does the research NOT show?
It is worth saying plainly what the human literature does not establish:
- That the peptides being pitched as substitutes are safer than anabolic-androgenic steroids in healthy adults. The human safety data on most of them is too thin to support that comparison either way.
- That BPC-157 or TB-500 produce the recovery effects routinely attributed to them in coaching content. The human trials to confirm those effects have not been run.
- That GH-axis peptides produce the body-composition outcomes implied in marketing copy, in healthy adults, on any meaningful timeline.
- That research-chemical-grade copies of any of these molecules behave the same way in the body as a sterile, tested, pharmacy-grade product.
Where the “softer” framing came from
The cultural rhetoric is older than the evidence behind it. Pieces of the framing started showing up in fitness content as early as 2015, mostly built on three ideas. First, that peptides are “natural” because they are short chains of amino acids, which is technically true and conveys nothing about safety or efficacy. Second, that the side effect profile is gentler, which is asserted more than it is demonstrated, especially for the GH-axis molecules at the higher levels being implied. Third, that peptides are “research-stage,” which somehow gets translated into “more cutting-edge” rather than “we do not yet know what we do not yet know.”
None of those three is wrong in a vacuum. All of them are misleading when stitched together as a substitution argument. The honest version of the framing is closer to: anabolic-androgenic steroids have known long-term risks that scale with age and length of use, and the peptides being offered as substitutes have unknown long-term risks because the trials have not been run. Trading a known risk for an unknown risk is a real trade. It is not necessarily a safer one.
The 2024 and 2025 narrowing of the 503A compounding pathway changed the source-safety landscape underneath this whole conversation. A lot of the peptide product that was flowing through the gray market in the early 2020s lost its legitimate channel. What is left is harder to source through compliant channels and easier to source through ones I am not going to name.
FDA and legal status of the peptides being pitched as substitutes
None of BPC-157, TB-500, Sermorelin, Ipamorelin, CJC-1295, or Hexarelin is FDA approved for the recovery, body-composition, or longevity uses implied in coaching content. Tesamorelin is approved for HIV-associated lipodystrophy. That indication does not generalize to healthy adults.
The 503A pathway narrowed sharply in 2024 and 2025. Several of the peptides discussed here landed on FDA’s Section 503A bulks list review, with some moving toward exclusion. This is a different legal posture than even three years ago.
Personal possession laws vary. None of these peptides are scheduled controlled substances. Most are sold gray-market under “research use only” labeling, which is a marketing posture, not a regulatory blessing.
Most of the peptides discussed here are explicitly prohibited under the World Anti-Doping Agency code, in or out of competition. If you are a tested athlete, this is a one-line answer. If you are not, the WADA listing is still a useful signal about how regulators view the risk-benefit picture.
The legal landscape for the peptides being pitched as anabolic substitutes is not the comfortable middle ground the marketing implies. They are largely not approved for the uses being suggested. The compounding pathway is narrower than it was. The “research use only” framing is a way of selling the product without taking responsibility for its use.
I built a doctor visit-prep one-pager for the recovery-and-longevity peptide conversation specifically. Evidence summary, what to ask, what to bring. Free PDF. No upsell.
Get the recovery-peptide visit-prep one-pagerHow to evaluate a source: the safety framework
Why this section exists: people are going to look for sources whether I help or not. My goal here is harm reduction, not facilitation. I do not name sellers. I do not link to anyone. I am teaching you how to think about a source so you can have an informed conversation with a clinician.
Green flags
- A licensed clinician who knows your full health history and is willing to say “this is not a good fit for you”
- For the narrow set with FDA-approved indications: a real prescription, filled at a licensed pharmacy
- Clear disclosure of where any compounded product is synthesized and tested
- Independent third-party testing made available, not just promised
- A clinician who frames the peptide conversation as part of a broader health picture, including labs, sleep, training, and recovery
Red flags
- Any source marketing peptides as a “softer alternative” to anabolic-androgenic steroids without acknowledging the human evidence gap
- “Research use only” labeling on a vial that is being marketed for human use
- Coaches recommending compounds outside any clinician relationship
- Urgency or scarcity language (“last batch”, “before the FDA shuts it down”)
- Refusal or inability to provide independent third-party lab testing
The wrinkle for this cultural shift specifically
The fitness coaching layer sits between the client and the clinician in a way that is unusual in healthcare. A coach is not a clinician, has no licensure for this conversation, and carries no liability for what happens after the recommendation. That is not an indictment of every coach. It is a structural fact about where this conversation usually happens, and it is worth holding in mind when you are weighing how seriously to take a coach’s framing of “softer.”
Cost reality
The cost gap between a licensed channel and the gray market is large, especially for the peptides whose 503A compounding pathway has narrowed. The price gap is doing a lot of the work pulling demand toward unregulated supply. The sterility, purity, and identity gap that comes with that price difference is real. There is no free lunch in this transaction.
Questions worth asking any source
Where is this synthesized? Where is it independently tested? Who is the prescribing clinician of record? What happens if I have a reaction? A real source has answers to those questions. A bad one has a logo and a payment processor.
My 503A Source-Safety Checklist is the single most useful tool on this site. Free PDF. No upsell. It is what I use myself.
Download the source-safety checklistMy honest take
This section is opinion, not evidence. I am not endorsing use of any peptide or any anabolic-androgenic compound. Everything above this line is sourced from published human research and regulatory documents. Everything below is my personal perspective as one pseudonymous reader. It is not medical advice. Your situation is not my situation. Do not treat this as a recommendation to try anything.
The cultural shift is real. I have watched it happen in the same content I have been reading for years. What I have not seen is the evidence layer catch up to the framing. The peptides being pitched as substitutes are not the peptides with the strongest human data, and the human data they do have does not say what the marketing says it says.
“Trading a known risk for an unknown risk is a real trade. It is not necessarily a safer one.”
What bothers me most about the rhetoric is the word “softer.” It is doing the work of three different claims at once. Softer than what, on what endpoint, over what timeline, in whom. The honest answer to all four is “we do not know.” That is not a damning answer. It is just an honest one. The marketing skips over it because the honest answer does not sell.
“The peptides with the strongest human evidence base are not the ones being pitched as anabolic substitutes. That mismatch is the whole story.”
If you are a person navigating this conversation, the thing I would push back hardest on is the idea that a coach can settle this question for you. They cannot. This is a clinician conversation, with your full history, your goals, and your stop conditions, not a YouTube conversation with someone whose business model depends on selling you the framing. I am writing this piece because nobody else seems to want to say that out loud.
Questions to ask your doctor
If you have read coaching content suggesting a “transition” toward peptides and you are taking that conversation seriously, here are the questions I would want answered before walking out of the appointment, in order.
- What is the actual human evidence for the peptide being suggested, in someone with my profile? If the answer cites animal studies as evidence of effect, that is not the evidence base the marketing implied.
- Is this peptide FDA approved for the use being suggested? For most peptides in this conversation, the honest answer is no. That is information you should have explicitly.
- What is the legitimate sourcing pathway in 2026, given the 503A changes? A clinician who has not noticed the 2024 to 2025 narrowing is a clinician operating on a stale map.
- What labs and markers will we follow, and what is our stop condition? A written plan beats a verbal “let me know if anything happens.” If the answer is vague, that is a flag.
- How does this interact with anything I am currently doing or have done in the past? Long histories matter, including ones that are uncomfortable to disclose. A real clinician makes that disclosure safe.
- If I decide not to do this, what is the alternative path that addresses the same underlying goal? If the only answer the conversation can produce is “do this peptide or do nothing,” the conversation is not happening with the right person.
I built a peptide-specific visit-prep packet to take into your appointment. Evidence summary, doctor questions, space for notes. Free PDF.
Get the visit-prep packetWhat to do next
If you are curious
Read the individual monographs on the peptides showing up in this conversation. Each one walks the human evidence in detail and flags where the framing outruns the data.
Read the BPC-157 monograph →If you are considering
Have the conversation with a clinician who knows your full history. Bring the visit-prep packet. Bring your stop condition before you start. A coach is not a substitute for that conversation.
Get the visit-prep packet →If you have decided
Use the source-safety checklist before committing to any provider or compounded product, especially given how the 503A landscape changed in 2024 and 2025.
Download the source-safety checklist →Sources
- US FDA. Section 503A bulks list nominations and Pharmacy Compounding Advisory Committee meeting materials, 2024 to 2025 review period.
- US FDA. Egrifta (Tesamorelin) prescribing information. Approved indication: HIV-associated lipodystrophy. Industry funded development (Theratechnologies).
- World Anti-Doping Agency. Prohibited List, current edition. Peptide hormones, growth factors, and related substances class.
- PubMed search audit, May 2026: BPC-157 yields zero published randomized controlled trials in humans as of writing.
- PubMed search audit, May 2026: TB-500 / Thymosin Beta-4 yields limited observational human data, primarily in ophthalmologic and dermatologic settings.
- Wilding JPH, et al. STEP 1. N Engl J Med. 2021;384:989-1002. Industry funded (Novo Nordisk). Cited as a counterpoint: the peptide with the strongest human evidence is not in the substitution conversation.
- Jastreboff AM, et al. SURMOUNT-1. N Engl J Med. 2022;387:205-216. Industry funded (Eli Lilly). Same counterpoint.
Funding for the strongest peptide trials is largely industry. That is worth saying plainly. Industry funding does not invalidate the data, but it is part of how the data should be read. The peptides without industry funding are also, in most cases, the peptides without much human data at all.
Related monographs
BPC-157
The recovery peptide with zero human RCTs and a reputation built on animal work.
TB-500
Limited observational human data, narrow clinical signals, broad marketing claims.
Tesamorelin
The GH-axis peptide with real human RCT data, in a narrow approved indication.
The Peptide File provides educational content based on published research. This article is not medical advice. The Peptide File does not sell, distribute, or facilitate the purchase of any peptide compound. Always work with a qualified healthcare provider.